1 and sephin1 as new allosteric modulators of acid-sensing ion 2 channel 3 3 4 Abstract 16
Introduction 45
Extracellular protons modulate the activity of a wide range of ion channels and 46 receptors, which activate sensory neurons involved in nociception and the development of pain [1] . One key group of proton sensors is the acid-sensing ion Whole-cell electrophysiology 145 Whole-cell patch clamp recordings from CHO cells were performed at room 146 temperature 24-hours after transfection. For all the experiments, the intracellular 147 solution contained (in mM) 110 KCl, 10 NaCl, 1 MgCl2, 1 EGTA, 10 HEPES, 2 148 Na2ATP, 0.5 Na2GTP in MilliQ water; pH was set to pH 7.3 by adding KOH and 149 the osmolality was adjusted to 310-315 mOsm with sucrose. The extracellular 150 solution contained (in mM) 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 4 151 Glucose in MilliQ water; osmolality was adjusted to 300-310 mOsm with sucrose 152 and pH was adjusted to 7.4 with NaOH. Patch pipettes were pulled from glass 153 capillaries (Hilgenberg) using a Model P-97, Flaming/Brown puller (Sutter 154 Instruments) and had a resistance of 4-8 MΩ. Data were acquired using an 155 EPC10 amplifier (HEKA) and Patchmaster software (HEKA) after suitable 156 resistance compensation. To measure the effect of the different selected the 1.9 Å crystal structure of chicken ASIC1 homotrimer (PDB id: 2QTS; [8]) as a 178 template. Detail of the model building was previously reported [48] . Selected 179 drugs were docked to the rASIC3 model using the Lamarckian genetic algorithm 180 (LGA) implemented in AutoDock 4.2.6 [49] . For all docking, an unbiased (''blind'') 181
docking approach was used where the entire rASIC3 trimer was used for 182 generating the grid map in AutoGrid. Prior to docking, structures of all drugs 183 (obtained from PubChem) and the rASIC3 trimer were prepared using the 184 AutoDock Tools. Five independent docking runs were performed for each drug 185 and the pose associated with the highest reproducibility and lowest predicted free Fitmaster. The sustained current to transient current ratio was calculated by 210 measuring the size of the sustained current (peak sustained response at the end 211 of the stimulus minus the 5-second mean baseline current) and dividing his value 212 by the peak amplitude current (Isus/Ipeak x 100). The analysis of ASIC3 current 213 amplitudes and kinetics was performed as previously reported [9] . Statistical 214 analysis was performed in GraphPad Prism using a paired t-test comparing the 215 baseline pH response (pA/pF) against the pH response after compound 216 application for each cell. Data were plotted as a percentage of the initial pH 217 response for each cell. Results are expressed as mean ± standard error of the 218 mean (SEM), unless otherwise stated. For dose-response curves, all 219 measurements were expressed as a percentage of the pH baseline peak current 220 value (pH 6 or pH 7). For pH-response curves, all measurements were 221 transformed to percent of the maximum peak current (I/Imax x 100). The EC50 for 222 
Ligand-based in silico screening of novel ASIC3 modulators
Effect of selected drugs on acid-induced rASIC3 activation.
262
The following set of experiments were conducted to determine if the selected 263 drugs modulate rASIC3 function. We performed whole-cell patch clamp 264 recordings in CHO cells co-transfected with rASIC3 and EGFP and evaluated the 265 effect of 30 s application of each drug (500 µM) on the rASIC3 response to pH 6. 266
In this series of experiments, we also evaluated the effect of GMQ and APETx2, 267 which were used as positive controls. As expected, in rASIC3-expressing CHO 268 cells, APETx2 (1µM) application did not activate the channel at neutral pH, but 269 produced a significant inhibition of transient (IPeak, Fig. 2A -B, n = 10, paired t-test, 270 p = 0.0013) and sustained (I5s, Fig. 2A , n = 10, paired t-test, p = 0.029) current 271 evoked by pH 6 (Table 1) . However, the ratio I5s/IPeak was significantly increased 272 (Fig 2C and Table 1 , n = 10, paired t-test, p = 0.036), indicating that the 273 predominant APETx2 inhibitory effect is exerted on the transient phase as 274 previously described [25] . In addition, APETx2 significantly inhibited the 275 inactivation time constant (Tau) of rASIC3 ( Fig. 2D and Table 1 , n = 10, paired t-276 test, p = 0.0005). By contrast, GMQ generated a sustained inward current at pH 277 7.4 as reported previously [21], but did not significantly modulate channel current 278 amplitude or inactivation kinetics (Table 1) . 279
280 Among the 5 drugs tested in these series of experiments (summarised in Table  281 1), with the exception of GBZ, none of them produced a significant change on 282 rASIC3 current amplitude or inactivation kinetics ( Fig. 2B-D) . Unlike all other 283 compounds tested, and in a similar fashion to GMQ, we observed that GBZ, a 284 drug currently used to treat hypertension, activated rASIC3 at neutral pH ( Fig.  285 2A). However, unlike GMQ, pre-application of GBZ elicited a significant increase 286 in the transient and sustained components of the pH 6-induced rASIC3 current 287 (Fig. 2B and Table 1 , IPeak, n = 11, paired t-test, p = 0.0173; I5s, n = 11, paired t-288 test, p = 0.015). The stronger potentiating effect upon the sustained current 289 (403%) compared with the effect on the transient current (113%) produced a 290 significant increase in the I5s/IPeak ratio ( Fig. 2C and Table 1 , n = 11, paired t-test, 291 p = 0.016) and the inactivation time constant of the pH 6-induced rASIC3 292 response was significantly increased by GBZ ( Fig. 2D and Table 1 , n = 11, paired Effect of GBZ on rat ASIC3 response to mild acidosis. 295 Millimolar concentrations of GMQ are required to activate rASIC3 channels at 296 neutral pH, but at micromolar concentrations, GMQ sensitises pH 7-induced 297 rASIC3 channel activation [21] . At neutral pH, even though both GMQ and GBZ 298
(1 mM), are capable of activating rASIC3, the activation of rASIC3 by GBZ is of 299 smaller magnitude compared to GMQ-induced rASIC3 activation (11 ± 1.6% for 300 GMQ vs 5 ± 1.1 for GBZ, Fig.3A and 3B ). Given the structural and chemical 301 similarities between GMQ and GBZ ( Fig. 1 ), we next tested the effect GBZ (500 302 µM) on pH 7-induced rASIC3 activation to determine if, like GMQ, it also 303 sensitises the pH 7 response of rASIC3. As expected, the application of GMQ 304 (500 µM) at pH 7 elicited a significant sensitisation of rASIC3 by increasing the 305 amplitude of both transient and sustained current components (Ipeak pH 7: 50 ± 306 5.9 pA/pF vs Ipeak pH 7 + GMQ: 203.4 ± 34.8 pA/pF, paired t-test, n = 9, p = 0.001; 307
I5s: 13.3 ± 1.5 pA/pF vs 132.5 ± 25.4 pA/pF, paired t-test, n = 9, p = 0.0012, Fig.  308 3C and 3D), and also increased the I5s/Ipeak ratio (I5s/Ipeak pH 7: 26.8± 1.2 % vs 309
I5s/Ipeak pH 7 + GMQ: 63.7 ± 2 %, paired t-test, n = 9, p < 0.0001, Fig. 3D ), 310
suggesting a stronger effect on the sustained component of rASIC3. Similarly, 311 GBZ (500 µM) potentiated the pH 7-induced rASIC3 activation (Ipeak pH 7: 159.3 312 ± 36 pA/pF vs Ipeak pH 7 + GBZ: 418.6 ± 103.5 pA/pF, paired t-test, n = 6, p = 313 0.038; I5s: 52.3 ± 9.6 pA/pF vs 342.1 ± 82.6 pA/pF, paired t-test, n = 6, p = 0.012; 314
I5s/Ipeak pH 7: 35 ± 4.9 % vs I5s/Ipeak pH 7 + GBZ: 81.3 ± 3.2 %, paired t-test, n = 315 6, p = 0.012, Fig. 3B and 3D ), suggesting a similar mechanism of rASIC3 316 modulation. However, as observed for the activation of rASIC3 at neutral pH, the 317 sensitising effect on the transient component of the pH 7-induced rASIC3 318 activation by GBZ was smaller than that elicited by GMQ, although the effect of 319 both molecules on the ratio I5s/Ipeak was of comparable magnitude (Ipeak GMQ: 320 408.1 ± 44.9 % vs Ipeak GBZ: 275.4 ± 25.3 %; I5s/Ipeak GMQ: 240.3 ± 9.1 % vs 321 I5s/Ipeak GBZ: 259.6 ± 42.5 %, Fig. 3D ). 322
323
The carboxyl-carboxylate interaction pair formed by the residues E79 and E423 324 in the palm domain of rASIC3 has been implicated in GMQ binding and the cavity 325 where these two amino acids are localised has been named the 'nonproton ligand certain structural and chemical properties with GMQ, including a guanidine 329 moiety ( Fig. 1B) , these molecules may or may not share the same binding site 330 or manifest similar binding mode to the same site on ASIC3. To address this 331 aspect, we performed in silico blind docking experiments with GMQ and GBZ 332 against our rASIC3 homology model [48] . In this unbiased docking approach, 333 GMQ preferentially docked to a pocket located in the palm domain of rASIC3 334 ( Fig.3E ) which has been computationally and experimentally established in 335 previous studies as the likely binding site for GMQ and designated as the 336 nonproton ligand sensor domain [21, 50] . In our hands, the guanidinium moiety of 337 GMQ seems to form two salt bridges with E423 whilst the 4-methylquinazoline 338 moiety makes a hydrophobic interaction with L77 and V425 ( Fig. 3F ). 339
Interestingly, GBZ also docked to the same location ( Fig. 3E ). Whilst similar salt 340 bridges are also retained in the best docked pose of GBZ, no comparable 341 hydrophobic interactions were discernible with L77 and V425, presumably due to 342 lack of an additional aromatic ring when compared to GMQ structure ( Fig.3F) . 343
344
Taken together, these results indicate that GBZ modulates rASIC3 in the mild 345 acidic range and that its binding site likely overlaps with that of GMQ, the so called 346 nonproton ligand sensor domain. However, their precise modes of binding may 347 be different, which may underlie the different potencies observed on rASIC3 348 current activation. in the eDrug3D database that we initially screened with ROCS using GMQ as 357 bait. ROCS-based alignment of sephin1 with GMQ revealed by far the highest 358 similarity among the 5 initially selected FDA-approved compounds in terms of 359 both 3D shape (>90%) and chemical features (>50%) with an overall TC score of 1.481 ( Fig. 4A ). In agreement with this, sephin1 appeared to be the most similar 361 to GMQ among all FDA-approved selected drugs in terms of the molecular field 362 points with the highest overall field score (Field Score = 0.847, Fig. 4B ). 363 364 Given the high molecular similarity observed in silico for sephin1 and GMQ/GBZ, 365
we evaluated the effect of sephin1 on the acid-induced rASIC3 response. Firstly, 366
we observed that sephin1 (500 µM) did not affect the transient component of pH 367 6-induced rASIC3 activation, but it did induce an increase in the amplitude of the 368 sustained component (Ipeak pH 6: 782.8 ± 98.5 pA/pF vs Ipeak pH 6 + sephin1: 369
775.1 ± 108.7 pA/pF, paired t-test, n = 10, p = 0.82; I5s pH 6: 4.3 ± 0.6 pA/pF vs 370
I5s pH 6 + sephin1: 11.2 ± 2.8 pA/pF, paired t-test, n = 10, p = 0.03, Fig. 4B and 371 4C) without significantly affecting the I5s/Ipeak ratio (I5s/Ipeak pH 6: 0.3 ± 0.1 pA/pF 372 vs I5s/Ipeak pH 6 + sephin1: 0.6 ± 0.2 pA/pF, paired t-test, n = 10, p = 0.13) or the 373 inactivation time constant (Tau: 301.4 ± 16.5 ms vs 336.9 ± 34.4 ms, paired t-374 test, n = 10, p = 0.09, Fig. 4C ) . Similarly to GMQ and GBZ, both 500 µM and 1 375 mM sephin1 also activated rASIC3 at neutral pH ( Fig. 4C and 4E insets) with an 376 EC50 of a similar magnitude to that described for GMQ (GMQ = 0.68 mM [21] vs. 377 sephin1 = 0.35 mM) ( Fig. 4F ). Furthermore, like GMQ and GBZ, sephin1 induced 378 a strong sensitisation, in a dose-dependent fashion, of the transient and 379
sustained components of the pH 7-induced rASIC3 activation ( Fig. 5A-D) , 380
revealing an EC50 of 28.93 µM for the rASIC3 transient current at pH 7 ( Fig. 5B) . 381
Given the high similarities in the action of sephin1 and GMQ, we hypothesized 382 that sephin1 also binds to the nonproton ligand sensor domain of rASIC3. 383
Similarly to GBZ, in silico blind docking experiments showed the likely interaction 384 of sephin1 with the E423 of the nonproton ligand sensor domain, but not E79, 385 together with possible hydrophobic interaction of the aromatic ring of sephin1 with 386 residue A378 ( Fig. 5E and 5F ). We next tested the pH dependency of rASIC3 387 modulation by sephin1. The application of different pH solutions ranging from pH 388 7.4 to 5 ( Fig. 5G and 5H) on rASIC3 induced currents of increasing magnitude to 389 produce a sigmoidal curve that could be fitted to reveal a pH50 value of 6.36 ( Fig.  390 5G inset), in accordance with previous reports [7, 52] . However, in the presence 391 of sephin1 (500 µM), rASIC3 transient activation followed a pH-dependent, using GMQ [21], sephin1 activated rASIC3 at neutral pH, but also potentiated its 395 sustained current at all pH solutions tested, showing a Gaussian distribution with 396 a peak at pH 6.56 (r 2 = 0.43, Fig. 5I ). Altogether, these results show that sephin1 397 modulates rASIC3 activation possibly through interacting with the nonproton 398 ligand sensor domain of the channel. 399
The ASIC family of ion channels have been implicated in many physiological and 401 pathological processes including nociception [53-55], where they have been 402 established as attractive pharmacological targets for treating pain. ASIC3 is 403 considered of particular interest given its high expression in primary sensory 404 neurones [10] and its involvement in inflammatory pain originating from different 405 tissues including muscle, joints and skin [26-28,56-58]. Therefore, the 406 exploration of novel ASIC3 modulators could increase our knowledge of ion 407 channel function and also be pivotal for the development of new strategies to 408 counteract the detrimental effects of dysregulated ASIC3 activity in 409 pathophysiological states. Many molecules that modulate ASIC3 function have 410 been discovered, ranging from non-selective ASIC3 blockers such as amiloride 411 that acts as a pore blocker and paradoxically stimulates ASIC3 at neutral pH [3], 412 to more specific molecules, such as the inhibitory toxin APETx2, which inhibits 413 the acid-induced transient ASIC3 current [25] , and the selective agonist GMQ, 414 which activates ASIC3 at neutral pH and potentiates its activation in response to 415 an acidic stimulus through the nonproton ligand sensor domain of ASIC3 [21, 61] . 416
In the present study, we used a ligand-based in silico screening of FDA-approved 417 drugs to identify novel rASIC3 modulators. Of the top 150 hits ranked by TC 418 score, we selected 5 different drugs with the highest structural and chemical 419 resemblance to GMQ ( Fig. 1A) , including the presence of a guanidine group. 420
Using an independent algorithm implemented in Cresset's ForgeÔ, we then 421 aligned these 5 drugs with GMQ and compared their surface electrostatic 422
properties represented by the molecular field points. Of the selected drugs, GBZ 423 showed a striking resemblance to GMQ with regard to surface electrostatics and 424 this was reflected in the highest observed value for the field score (0.80). Of the 425 remaining 4 drugs, only BRI which had the 2 nd best field score, showed some 426 degree of electrostatic similarity with GMQ ( Fig.1B) . 427
428
We next sought to experimentally evaluate the effects of these drugs on acid-429 induced rASIC3 activation. Only one of the drugs tested showed a modulatory 430 effect on rASIC3 acid response to pH 6, namely GBZ, an α2-adrenoceptor selected (Fig. 1) , together with the presence of an explicit guanidine group. 434
Interestingly, TIZ and BRI that showed a higher TC score ( Fig. 1A; 1 .047 and 435 1.161, respectively) than GBZ and a lower field score in terms of surface 436 electrostatics but the presence of an implicit guanidine moiety (Fig. 1B) , did not 437 modulate rASIC3 function, suggesting that a combination of structural and 438 chemical similarities with GMQ and the presence of an explicit guanidine group 439 are required to modulate ASIC3. Nevertheless, it was perhaps unsurprising to 440 observe that GBZ followed a similar mode of action to GMQ, being capable of 441 activating rASIC3 at neutral pH ( Fig. 2A and 3A) and inducing a non-desensitising 442 inward current, however its potency was lower than that described for GMQ. 443
Based on our findings from the blind docking experiments against the rASIC3 444 homology model (Fig. 3E) , this difference could be explained by the lack of 445 interaction with the core residue L77 and the adjacent residue V425. Such 446
interactions are observed for GMQ in our docking experiment ( Fig. 3F ) and have 447 been previously shown to be important in the interaction of the 4-448 methylquinazoline moiety of GMQ [61].This is plausible because, unlike GMQ, 449 GBZ lacks a second aromatic moiety in an appropriate position to allow such 450 hydrophobic contacts. Moreover, the sensitisation of the pH 6-induced rASIC3 451 activation observed by GBZ ( Fig. 2A and 2B) intention of identifying a more selective rASIC3 modulator without adrenoceptor 475 activity, we tested the effect of sephin1 on acid-induced rASIC3 activation. We 476 observed that sephin1 shared a similar pharmacological profile with GBZ and 477 GMQ, sensitising the response (sustained component) of rASIC3 to low pH (pH 478 6) ( Fig. 4C and 4D ) and mild acidosis (pH 7) ( Fig. 5A-D) , and activating rASIC3 479 at neutral pH (Fig.4E) . These results were consistent with our expectations given 480 that sephin1 appeared to be most similar to GMQ in terms of structural and 481 chemical properties, exhibiting the highest TC score (Fig. 4A) , and in terms of 482 molecular field points with the highest overall field score (Fig. 4B) . Moreover, 483 increasing concentrations of sephin1 induced increasing potentiation of the pH 7-484 induced rASIC3 activation (Fig. 5A ). Our docking experiments indicated that 485 sephin1 is likely to bind to the nonproton ligand sensor domain and, as we 486 observed for GMQ and GBZ, the negatively charged residue E423 is likely to 487 interact with the explicit guanidinium group of sephin1 ( Fig. 5E and 5F ). However, 488 compared to GBZ, sephin1's lack of a chloride atom in the aromatic ring seems 489 to allow it to make hydrophobic interactions with surrounding residues like A378, 490 but not with L77 and Val425 as observed for GMQ ( Fig.3F) . Overall, these 491 interactions likely underlie differential recognition of sephin1 at the nonproton 492 ligand sensor domain of ASIC3, compared to that of GMQ and GBZ. 493 494 Sephin1 is able to selectively disrupt the PPP1R15A-PP1c complex at 50 µM in 495 cells in vitro and after oral administration, sephin1 accumulates in the nervous 496 system reaching concentrations of up to 1 µM in the brain and sciatic nerve [51] . 497
Moreover, a 2-week treatment with sephin1 at 100 nM has shown efficacy in 498 rescuing myelination of the dorsal root ganglia in a mouse model that mimics expression of rASIC3 in DRG neurones and its involvement in pain derived from 501 inflammatory diseases, together with the action of sephin1 observed on the 502 channel, it is possible that sephin1 treatment could induce and/or exacerbate pain 503 due to the activation of ASIC3 in DRG neurones, however our results show that 504 both activation of rASIC3 at neutral pH and potentiation of the response to mild 505 acidosis (pH 7) require higher concentrations of sephin1 ( Fig. 4F and 5A) than 506 those observed to be beneficial in treating misfolding protein diseases in mice. Given the pharmacological and structural resemblance of sephin1 to GMQ, it is 519 possible that sephin1 induces similar modulatory effects on other ASIC subunits. 520
Nevertheless, we believe that the evaluation of pain thresholds in mice and 521 humans used to study the effect of sephin1 in misfolding protein disease should 522 be considered in future studies. 523
524
In summary, we have identified new rASIC3 modulators using a ligand-based in 525 silico approach, namely GBZ and sephin1, and evaluated their effect on rASIC3 526 function using electrophysiology. Here we provide proof of principle, using a size-527 restricted chemical library (i.e. FDA-approved drug library), but believe this 528 approach can be exploited in the future to screen much larger chemical space, 529 enabling the identification of novel chemical scaffolds that act as ASIC 530 modulators. 
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